Issue 39, 2014

The first synthesis of the antiangiogenic homoisoflavanone, cremastranone

Abstract

An antiangiogenic homoisoflavanone, cremastranone, was synthesized for the first time. This scalable synthesis, which includes selective demethylation, could be used to develop lead molecules to treat angiogenesis-induced eye diseases. Synthetic cremastranone inhibited the proliferation, migration and tube formation ability of human retinal microvascular endothelial cells, important steps in pathological angiogenesis.

Graphical abstract: The first synthesis of the antiangiogenic homoisoflavanone, cremastranone

Supplementary files

Article information

Article type
Communication
Submitted
28 Jul 2014
Accepted
18 Aug 2014
First published
19 Aug 2014

Org. Biomol. Chem., 2014,12, 7673-7677

Author version available

The first synthesis of the antiangiogenic homoisoflavanone, cremastranone

B. Lee, H. D. Basavarajappa, R. S. Sulaiman, X. Fei, S. Seo and T. W. Corson, Org. Biomol. Chem., 2014, 12, 7673 DOI: 10.1039/C4OB01604A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements